indication

Used in short-term (a few weeks) treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m²) or in patients with a body mass index of 27 kg/m² in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia.

pharmacology

Mazindol is a sympathomimetic amine, which is similar to an amphetamine. Mazindol stimulates the central nervous system (nerves and brain), which increases your heart rate and blood pressure and decreases your appetite. Sympathomimetic appetite suppressants are used in the short-term treatment of obesity. Their appetite-reducing effect tends to decrease after a few weeks. Because of this, these medicines are useful only during the first few weeks of a weight-loss program.

mechanism of action

Although the mechanism of action of the sympathomimetics in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Unlike other sympathomimetic appetite suppressants such as phentermine, mazindol is thought to inhibit the reuptake of norepinephrine rather than to cause its release.

toxicity

Symptoms of a mazindol overdose include restlessness, tremor, rapid breathing, confusion, hallucinations, panic, aggressiveness, nausea, vomiting, diarrhea, an irregular heartbeat, and seizures.

biotransformation

Hepatic.

half life

10-13 hours

drug interactions

Acetophenazine: Decreased anorexic effect, may increase psychotic symptoms

Chlorpromazine: Decreased anorexic effect, may increase psychotic symptoms

Ethopropazine: Decreased anorexic effect, may increase psychotic symptoms

Fluoxetine: Risk of serotoninergic syndrome

Fluphenazine: Decreased anorexic effect, may increase psychotic symptoms

Fluvoxamine: Risk of serotoninergic syndrome

Guanethidine: Mazindol may decrease the effect of guanethidine.

Isocarboxazid: Possible hypertensive crisis

Mesoridazine: Decreased anorexic effect, may increase psychotic symptoms

Methdilazine: Decreased anorexic effect, may increase psychotic symptoms

Methotrimeprazine: Decreased anorexic effect, may increase psychotic symptoms

Paroxetine: Risk of serotoninergic syndrome

Perphenazine: Decreased anorexic effect, may increase psychotic symptoms

Phenelzine: Possible hypertensive crisis

Prochlorperazine: Decreased anorexic effect, may increase psychotic symptoms.

Promazine: Decreased anorexic effect, may increase psychotic symptoms

Promethazine: Decreased anorexic effect, may increase psychotic symptoms.

Propericiazine: Decreased anorexic effect, may increase psychotic symptoms.

Propiomazine: Decreased anorexic effect, may increase psychotic symptoms

Rasagiline: Possible hypertensive crisis

Thiethylperazine: Decreased anorexic effect, may increase psychotic symptoms

Thioridazine: Decreased anorexic effect, may increase psychotic symptoms

Tranylcypromine: Possible hypertensive crisis

Trifluoperazine: Decreased anorexic effect, may increase psychotic symptoms

Triflupromazine: Decreased anorexic effect, may increase psychotic symptoms

Trimeprazine: Decreased anorexic effect, may increase psychotic symptoms

Venlafaxine: Risk of serotoninergic syndrome